Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN-001 + avelumab
- Development stage
- Unknown
- Lead developer
- Genome & Company
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
**GEN-001 + avelumab** is a combination therapy comprising a live biotherapeutic product, GEN-001—a single-strain live lyophilized *Lactococcus lactis*—and avelumab, a monoclonal antibody targeting PD-L1. GEN-001 is designed to enhance anti-tumor immunity through modulation of the gut microbiota, promoting dendritic cell activation, improved antigen presentation, and inflammatory cytokine production. Avelumab acts as a checkpoint inhibitor by blocking the interaction of PD-L1 with PD-1 on T-cells, restoring anti-tumor immune responses. This combination is in phase 2 development for the treatment of patients with PD-L1–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, showing promising anti-tumor activity and a manageable safety profile[1][5][7].
- Brand names
- Bavencio
- Other names
- GEN-001 plus avelumabGEN001 plus avelumabGEN 001 plus avelumabGEN-001/avelumab
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on GEN-001 + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN-001 + avelumab.